Form 4: Galectin Therapeutics Director Kevin D. Freeman Buys Additional Shares
SEC Form 4
Director Kevin D. Freeman of Galectin Therapeutics Inc. reports purchasing 2,500 shares of common stock at $2.3799 per share.
Summary
- On June 20, 2024, Kevin D. Freeman, a director of Galectin Therapeutics Inc., purchased 2,500 shares of common stock at a price of $2.3799 per share.
- Following this transaction, Freeman directly owns 28,469 shares.
- Freeman also indirectly owns 75,000 shares through Freeman Global Holdings LLC and 18,063 shares through an IRA.
Sentiment
Score: 6
Explanation: The sentiment is neutral to slightly positive. A director purchasing shares suggests confidence, but it's a relatively small transaction.
Positives
- A director's purchase of company stock can be seen as a positive signal, indicating confidence in the company's future prospects.
Industry Context
This filing is a routine disclosure of insider trading activity, which is common in the pharmaceutical industry. Monitoring such filings can provide insights into management's sentiment and confidence in the company's performance.
Stakeholder Impact
- The stock purchase could have a minor positive impact on shareholder sentiment.
Key Dates
| Date | Description |
|---|---|
| 06/20/2024 | Date of transaction: Kevin D. Freeman purchased 2,500 shares of common stock. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.